These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15650431)

  • 1. Sequence variability of the HIV type 1 protease gene in thai patients experienced with antiretroviral therapy.
    Nukoolkarn S; Pongthapisith V; Panyim S; Leelamanit W
    AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1368-72. PubMed ID: 15650431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors.
    Jinnopat P; Isarangkura-na-ayuthaya P; Utachee P; Kitagawa Y; de Silva UC; Siripanyaphinyo U; Kameoka Y; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):320-8. PubMed ID: 19727001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and distribution of HIV type 1 genetic diversity and protease inhibitor resistance-associated mutations in Shanghai, P. R. China.
    Zhong P; Kang L; Pan Q; Konings F; Burda S; Ma L; Xue Y; Zheng X; Jin Z; Nyambi P
    J Acquir Immune Defic Syndr; 2003 Sep; 34(1):91-101. PubMed ID: 14501800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained appearance of drug resistance-associated mutations in HIV-1 CRF01_AE protease and reverse transcriptase derived from protease inhibitor-naive Thai patients.
    Jullaksorn D; Boonchawalit S; Uttiyoung J; Soonthornsata B; Yowang A; Krathong N; Chautrakul S; Ikuta K; Roobsoong A; Kanitvittaya S; Sawanpanyalert P; Kameoka M
    Southeast Asian J Trop Med Public Health; 2010 Mar; 41(2):347-57. PubMed ID: 20578518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response.
    Ojesina AI; Sankalé JL; Odaibo G; Langevin S; Meloni ST; Sarr AD; Olaleye D; Kanki PJ
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):770-9. PubMed ID: 16910833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
    Martinez-Cajas JL; Wainberg MA; Oliveira M; Asahchop EL; Doualla-Bell F; Lisovsky I; Moisi D; Mendelson E; Grossman Z; Brenner BG
    J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
    Bally F; Martinez R; Peters S; Sudre P; Telenti A
    AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.
    Kantor R; Katzenstein D
    AIDS Rev; 2003; 5(1):25-35. PubMed ID: 12875105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
    Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
    Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G.
    Palma AC; Abecasis AB; Vercauteren J; Carvalho AP; Cabanas J; Vandamme AM; Camacho RJ
    Infect Genet Evol; 2010 Apr; 10(3):373-9. PubMed ID: 19577015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure.
    Manosuthi W; Butler DM; Pérez-Santiago J; Poon AF; Pillai SK; Mehta SR; Pacold ME; Richman DD; Pond SK; Smith DM
    AIDS; 2010 Jan; 24(3):411-6. PubMed ID: 20009919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand.
    Poonpiriya V; Sungkanuparph S; Leechanachai P; Pasomsub E; Watitpun C; Chunhakan S; Chantratita W
    J Virol Methods; 2008 Jul; 151(1):79-86. PubMed ID: 18462814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of drug resistance-related polymorphisms in treatment-naive individuals infected with nonsubtype B HIV type 1 in Cameroon.
    Youngpairoj AS; Alemnji GA; Eno LT; Lyonga EJ; Eloundou MA; Shanmugam V; Mpoudi EN; Folks TM; Kalish ML; Pieniazek D; Fonjungo PN
    AIDS Res Hum Retroviruses; 2012 Jul; 28(7):675-84. PubMed ID: 21923557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
    Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
    J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the protease sequences of HIV-1 infected individuals after Indinavir monotherapy.
    Sa-Filho DJ; Costa LJ; de Oliveira CF; Guimarães AP; Accetturi CA; Tanuri A; Diaz RS
    J Clin Virol; 2003 Oct; 28(2):186-202. PubMed ID: 12957189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.
    Servais J; Lambert C; Karita E; Vanhove D; Fischer A; Baurith T; Schmit JC; Schneider F; Hemmer R; Arendt V
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):279-83. PubMed ID: 15117451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union.
    Vázquez de Parga E; Rakhmanova A; Pérez-Alvarez L; Vinogradova A; Delgado E; Thomson MM; Casado G; Sierra M; Muñoz M; Carmona R; Vega Y; Contreras G; Medrano L; Osmanov S; Nájera R
    J Med Virol; 2005 Nov; 77(3):337-44. PubMed ID: 16173024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.
    Tanuri A; Vicente AC; Otsuki K; Ramos CA; Ferreira OC; Schechter M; Janini LM; Pieniazek D; Rayfield MA
    Antimicrob Agents Chemother; 1999 Feb; 43(2):253-8. PubMed ID: 9925514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.